Drugs / LATIKAFUSP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04362748 | Sep 2020 → Sep 2023 | cancer | Amgen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LATIKAFUSP | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095129 ↗ |
| Known as | AMG 256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04362748 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095129 ↗ |
| Route | Intravenous | “AMG 256 administered as an intravenous (IV) infusion.” NCT04362748 ↗ |